### Administration of Subcutaneous Furosemide for Palliative Patients in Community Settings in Bradford, Airedale, Wharfedale and Craven

**Guideline (Dec 19)**

<table>
<thead>
<tr>
<th>Document Authors:</th>
<th>Tracey Hellawell, ANHSFT Sharon Grimsdale, BTHFT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assurance Group:</td>
<td>Nursing and Midwifery Governance Group</td>
</tr>
<tr>
<td>PDRG:</td>
<td></td>
</tr>
<tr>
<td>Date Issued:</td>
<td></td>
</tr>
<tr>
<td>Target Audience:</td>
<td>Heart Failure patients who - have had a limited response to oral diuretics - are unable to take oral diuretics - Palliative for symptom control</td>
</tr>
<tr>
<td>People Authorised To Use This Guideline:</td>
<td>Heart Failure Nurse Specialists Community Advanced Nurse Practitioners / Matrons Community Collaborative Care Teams District Nursing Teams</td>
</tr>
<tr>
<td>Document Author Roles:</td>
<td>Heart Failure Nurse Specialist (Community)</td>
</tr>
<tr>
<td>Date Approved by Assurance Group:</td>
<td></td>
</tr>
<tr>
<td>Ratification Date:</td>
<td></td>
</tr>
<tr>
<td>Review Date:</td>
<td></td>
</tr>
<tr>
<td>Equality Impact Analysis:</td>
<td></td>
</tr>
<tr>
<td>Training Requirement To Use This Guideline:</td>
<td>Education session to support S/C Diuretic use</td>
</tr>
<tr>
<td>People Authorised To Use This Guideline:</td>
<td></td>
</tr>
<tr>
<td>Corporate Issues:</td>
<td></td>
</tr>
<tr>
<td>Clinical Governance Issues:</td>
<td></td>
</tr>
<tr>
<td>People Governance Issues:</td>
<td></td>
</tr>
<tr>
<td>Risks Identified With Using This Guideline:</td>
<td></td>
</tr>
<tr>
<td>Risk Counter Measures:</td>
<td></td>
</tr>
<tr>
<td>GUIDELINE CHECKED FOR:</td>
<td>Yes/No</td>
</tr>
</tbody>
</table>

**GUIDELINE REVIEW HISTORY**

<table>
<thead>
<tr>
<th>Version No:</th>
<th>Review Date:</th>
<th>Reviewer:</th>
<th>Changes Made:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If printed, this Guideline is **valid on the day of printing only**. Please ensure that you check AireShare to ensure you are using the current version.

Administration of Subcutaneous Furosemide for Palliative Patients Guideline (Dec19)
## Table of Contents

1. **Introduction**
   
2. **Advantages to the patient**
   
3. **Indications for Use (not all symptoms may be present)**
   
4. **Recommended Infusion Sites**
   
5. **Recommended Dose**
   
5.1 **Current Doses of Furosemide Ampoules Available**
   
5.2 **Contra-indications and side effects**
   
5.3 **Observe for signs of dehydration**
   
5.4 **Observe for signs of decompensated heart failure**
   
5.5 **Monitoring**
   
5.6 **Treatment Goals**
   
5.7 **Potential Side Effects**
   
6. **Support**
   
6.1 **For further advice contact**
   
7. **References Available**
   
8. **Bibliography**
   
9. **Acknowledgements**
   
10. **Procedural Document Development Checklist**
1 INTRODUCTION

Airedale NHS Foundation Trust fully recognises that the obligation to implement guidance should not override any individual clinician to practice in a particular way if that variation can be fully justified in accordance with Bolam Principles. Such variation in clinical practice might be both reasonable and justified at an individual patient level in line with best professional judgement. In this context, clinical guidelines do not have the force of law. However, the Trust will expect clear documentation of the reasons for such a decision and for this variation. In addition, any decision by an individual patient to refuse treatment in line with best practice must be respected, escalated to the consultant and fully documented in the appropriate records of care/treatment.

2 ADVANTAGES TO THE PATIENT

The patient, relatives and carers should be given an explanation of how this method of drug administration benefits the individual patient and consent should be obtained, when possible, from the patient or carers if the patient is too unwell, before administration is commenced.

It avoids the necessity of intermittent intravenous or intramuscular injections of Furosemide and the siting of a cannula. The syringe drivers used are lightweight, allow mobility and continued independence. The twenty-four hour infusion reduces intrusion into the patient’s privacy. It allows community staff to plan care around the timing of the infusion change. It allows the patient to be discharged from hospital when there is a continuing need for parenteral therapy.

3 INDICATIONS FOR USE (NOT ALL SYMPTOMS MAY BE PRESENT)

- Increased dyspnoea at rest, PND
- Increased cough, productive white phlegm
- Increased peripheral oedema
- Ascites
- Failing to respond to increased oral diuretics

For palliative patients requiring parenteral diuretics and:

- their preferred place of care* is own home, nursing home, hospice or residential home
- poor or no venous access
- to allow discharge from hospital when the patient has an ongoing need for parenteral diuretics
- Palliative patient for symptom control - SC diuretics offers these patients more participation and choice in treatment decisions regarding their preferred place of care

*This assumes that this is an appropriate option and hospital admission would not confer additional benefit at the patient’s stage of illness, or the patient refuses admission after due discussion of the options.
4 RECOMMENDED INFUSION SITES

Upper chest
Upper anterior aspect of arms

Sites are restricted in heart failure patients due to gross oedema. The abdomen is not recommended where abdominal ascites is present therefore recommended infusion sites must be used. Also sites to be avoided are bony prominences and areas where tissue is damaged, thus decreasing absorption. If possible, use a site away from areas where tattoos are present as these may mask site reactions. Monitor for signs of inflammation / infection / rash and hardening of skin at entry site which can be quite painful if treatment is prolonged.

**Cannula can be left insitu for 72 hours or longer if no redness** (Refer to VIP Score)

Follow BDCT / ANHST Syringe driver policy for use of syringe driver.

**If there is very poor peripheral perfusion in the terminal stage, subcutaneous absorption may be limited and stat doses of intramuscular diuretics or alternative measures such as antimuscarinics, buccal nitrates or sedation may be needed to alleviate terminal pulmonary oedema.**

5 RECOMMENDED DOSE

It may be appropriate to have recent urea and electrolytes prior to commencement of Subcutaneous Furosemide and repeated as required according to clinical assessment. Use the previous oral 24 hour requirement as a start dose and titrate up or down according to response, reviewed every 24 hours.

* It is important to recognise that this approach is entirely empirical as there is no published literature to help guide the clinician with this regard and this recommendation is based on clinical experience of the local team to date. It may be necessary to liaise with the Cardiologist / Palliative Care Consultant for appropriate treatment regime.

eg: If the patient has been taking Furosemide 120mg mane, 80mg mid-day daily, start on 200mg/24 hours in the syringe driver.

**Furosemide 200mg SC infusion**

50mg/5ml ampoules x 4 = 200mg in 20mls to infuse over 24 hours

5.1 Current Doses of Furosemide Ampoules Available:

Furosemide 250mg/25ml solution for injection (equals 10mg/ml)
Furosemide 50mg/5ml solution for injection
Furosemide 20mg/2ml solution for injection

- Choose the appropriate luer lock syringe size for the volume to be infused (Usually 20ml or 30ml is recommended)
- Infusion can be given neat
- If appropriate a diluent may be used of Sodium Chloride 0.9% as per local policy.
- The solution should be infused following the guidelines for the local syringe driver.
- The syringe driver should be stored in a locked box whilst infusing (ANHSFT only).
- Drug stability – Exposure to light may cause degradation and discolouration, the solution should not be used if a yellow colour is present.

**Furosemide MUST NOT be mixed with any other medications**
Plan to maintain on current regime and reduce dose when clinically appropriate. If SC dose is reduced please consider / introduce oral dose alongside, for example:

<table>
<thead>
<tr>
<th>SC Furosemide dose</th>
<th>Oral dose to commence</th>
</tr>
</thead>
<tbody>
<tr>
<td>100mg</td>
<td>0mg</td>
</tr>
<tr>
<td>80mg</td>
<td>40mg</td>
</tr>
<tr>
<td>60mg</td>
<td>80mg</td>
</tr>
</tbody>
</table>

The dose should be reviewed by initiating healthcare prescribing professional and adjusted accordingly. Guidance can also be sought from the Acute Hospital Cardiologist, switchboard to bleep or contacting Palliative Care Consultant.

If, on review, subcutaneous administration appears to be ineffective with regard to symptom control, a clinical reassessment and judgement will be repeated and the future management plan negotiated with the patient and family as appropriate.

5.2 Contra-indications and side effects

As listed in the BNF. In situations of symptom management/palliative care the prescribing physician will consider the best interests of the patient.

5.3 Observe for signs of dehydration

- dizziness
- blurred vision
- excessive thirst
- diarrhoea / constipation
- vomiting
- increased fatigue / increased weakness
- increased lethargy

5.4 Observe for signs of decompensated heart failure

(Consider may have some signs already)

- increased breathlessness at rest
- increased cough, productive – white phlegm
- evidence of increased peripheral oedema – ankles/thighs/sacral pad/abdomen

Ensure syringe driver is infusing appropriately. Monitor VIP Score. Ensure oral fluid intake is limited to 1.5-2 litres (or less) as directed daily.

If any concerns with above symptoms please contact the appropriate prescribing physician.

5.5 Monitoring

Record BP, Pulse, Weight if clinically indicated
Obtain venous blood samples if directed (but not routinely)

It may not be appropriate to carry out blood tests / observations on patients in the palliative stage of heart failure as the results are unlikely to affect treatment decisions which are purely aimed at symptom control.
5.6 Treatment Goals

It is hoped that
1) The infusion will initiate an increase in diuresis as absorption will be more effective.
2) Patient less dyspnoeic on exertion, symptomatic improvement in breathing
3) Reduction in peripheral oedema
4) Weight reduction, attainment of a target / goal weight (if appropriate to undertake)
5) Maintain stable renal function if appropriate
   (K+>3.5<5.5mmols, Na>125mmols/l, Creatinine <300μmol/l or increases by no more than 50%)

5.7 Potential Side Effects

Patients would be fully informed by the Heart Failure Nurse Specialist of possible side effects prior to starting this treatment at home. The risk of side effects will vary between patients and this treatment would only be given in the community setting if the MDT and patient agreed it would be safe to do so.

6 SUPPORT

The patient, relatives and carers should be given an explanation of how this method of drug administration benefits the individual patient and consent.

If the syringe driver does not appear to be working, the carers/patient should be advised to contact the District Nurse Team through Single Point of access number or their GP (in normal hours).

The Healthcare Prescribing Professional will review the patient at appropriate intervals during the duration of the infusion and work closely with the District Nursing Team involved in delivering the diuretic infusion.

All treatment / care delivery and health professional input will be documented on SystmOne. The patient will be given an explanatory leaflet relevant to local area.

6.1 For further advice contact:

<table>
<thead>
<tr>
<th>Airedale</th>
<th>Bradford</th>
</tr>
</thead>
</table>
| Heart Failure Nurse Specialist  
(if known to service): | Named Heart Failure Nurse Specialist  
(if known to service) |
| 01535 294555 (answer machine available)  
Monday – Friday 8.00 am – 5.00 pm | Marie Cure Hospice: 01274 337000 |
| Manorlands: 01535 642308 | Bradford Teaching Hospital Cardiology  
Consultant / Registrar on call  
(via switchboard): 01274 552200 |
| Airedale Hospital Cardiology Consultant  
/Registrar on call (via switchboard): 01535 652511 | Single Point Access (SPA) - 24 hour availability: 01274 256131 |
| Single Point Access (SPA) – 24 hour availability: 01274 256131 | Patient own GP Practice |
| Patient own GP Practice | NHS Helpline: 111 |
| NHS Helpline: 111 | |
7 REFERENCES AVAILABLE:

To date few references are available pertaining to administration of subcutaneous Furosemide.

Diuretic Effects of Subcutaneous Furosemide In Human Volunteer: A Randomised Pilot Study.
Arun K Vernea; Jack H Da Silva; David R Kuhl
The Annals of Pharmacology 2004

Furosemide

Management of End Stage Cardiac Failure
M J Johnson
Post Graduate Medical Journal June 2007; 83(980): 395-401

Subcutaneous administration of drugs in the elderly: Survey of practice and systematic literature review
C Fonzo-Christe; C Vukasovic; A Wasilewski-Rosca; P Bonnabry

Subcutaneous Furosemide
M A Goenaga; M Millett; E Sanchez; C Gorde; JA Carrera; E Arzellus
Annals of Pharmacotherapy October 1 2004, 38 (10), p1751

Subcutaneous Furosemide in advanced heart failure: has clinical practice run ahead of the evidence base?
J M Beattie, M J Johnson
British Medical Journal Supportive and Palliative Care 2012, 2, 5-6

8 BIBLIOGRAPHY

Improving Outcomes In Chronic Heart Failure
Simon Stewart, Linda Blue
BMJ Books 2004

Heart Failure and Palliative Care a team approach
Miriam Johnson and Richard Lehman 2006

The Royal Marsden Manual of Clinical Nursing Procedures Fifth Edition

BNF – Current edition
9 ACKNOWLEDGEMENTS

Sharon Grimsdale, Heart Failure Nurse Specialist, Bradford Teaching Hospitals NHS Foundation Trust

Tracey Hellawell, Heart Failure Nurse Specialist, Airedale NHS Foundation Trust

Dr Sarah Holmes, Consultant in Palliative Care, Marie Curie Hospice, Bradford

Dr Linda Wilson, Consultant in Palliative Care, Airedale NHS Trust

Belinda Marks, Clinical Lead Palliative Care, Bradford District Care Trust

Dr Bulu, Consultant Cardiologist, Bradford Teaching Hospitals NHS Foundation Trust

Dr Gosai, Consultant Cardiologist, Bradford Teaching Hospitals NHS Foundation Trust

Dr Hossam Elmahy, Consultant Cardiologist, Airedale NHS Foundation Trust
10 PROCEDURAL DOCUMENT DEVELOPMENT CHECKLIST

Prior to submitting any document for initial ratification or following a review, the following checklist must be completed and appended by the author to the document. Please remember when writing a procedural document you need to be as specific as possible and not leave any area open for misinterpretation.

<table>
<thead>
<tr>
<th>TITLE OF DOCUMENT:</th>
<th>✓</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front page – title, document reference table</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Is the title clear and unambiguous?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Is it clear whether the document is a guideline, policy, or SOP?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Has the correct document template been used?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Is the document reference table completed?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Is the review date identified?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Is the frequency of review identified? If so, is it acceptable?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Contents page and associated trust documents</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Are the contents page and page numbers accurate?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Are all associated trust documents hyperlinked?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Are the intention, purpose and scope of the document made clear?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Are all relevant, supporting policies, local and national guidelines and SOPs listed?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Has an equality impact assessment been completed?</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Definitions</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Are all terms clearly defined?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Duties</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Are all roles and responsibilities made clear?</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Developing a new procedural document</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Have any training needs been identified?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>If so, have Education &amp; Training / practice development been consulted?</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>